Blogs about: X Renal
Featured Blog
Pervasis Therapeutics, Inc.: Series B $9.75M
Pervasis Therapeutics (Cambridge, MA) is working to regulate vascular repair and restore natural blood flow to critical organs in end-stage renal disease closed a $9.75M Series B financing. Participan… more →
OnBioVC
Pervasis Therapeutics, Inc.: Series B $9.75M
arubenstein wrote 1 year ago: Pervasis Therapeutics (Cambridge, MA) is working to regulate vascular repair and restore natural blo … more →
